Overview

Dementia Associated with Alzheimer’s Disease Market is estimated to value over CAGR of over 4.3% during the forecast period 2020 to 2027.

Factors which have been anticipated to boost the dementia associated with Alzheimer’s disease market growth includes growing geriatric population, a hike in the presence of Alzheimer’s disease on a scale, boost in the research and development expenditure and plenty of alternatives in treatment. In addition, an abundance of research and development endeavors in disease altering drugs and an augmentation in investment by major market players in clinical studies pertinent to enhanced treatment alternatives are instrumental in the expansion of the market size during the forecast time frame. Although, the exorbitant costs of the enhanced treatment facilities as well as the detrimental side-effects linked with specific treatments count as some of the reasons that may restrain the market growth.

Going by the segmentation of the drug class, the market is fragmented into memantine, combined drug (donepezil & memantine), cholinesterase/cholinergic, inhibitor and others. In the segment of cholinesterase/cholinergic inhibitor, it is to be observed this segment is controlling the market size of dementia associated with Alzheimer’s disease. This inhibitor, in value terms, is the first phase of treatment for AD and is a commonly prescribed drug for AD. This segment is predicted to experience considerable CAGR, in part, because of the positive attributes in the treatment of dementia ranging from mild to severe. At present, there is no known treatment that can alter the Alzheimer’s disease, and the treatments that does exist for AD relief are known as cholinesterase inhibitors.

The segment for memantine is estimated to grow at a considerable CAGR, due to the properties that it contains to treat AD that is moderate to severe.

With the distribution channel segment, it has been bifurcated into retail, hospital and online pharmacies. The hospital pharmacies are expected to capture significant market share during the forecast timeline owing to affordable medication. The online pharmacies is estimated to encounter high growth since there is an easy accessibility of drugs at the comfort of one’s home at a reduced rate.

Key players who dominate this market includes Ono Pharmaceutical Co., Eisai Co., Ltd., Johnson & Johnson Services, Inc., Novartis AG, Allergan plc., Merz Pharma GmbH & Co. KGaA., F. Hoffmann-La Roche Ltd, Daiichi Sankyo Company, Pfizer, Inc., Limited, Ltd, H. Lundbeck A/S.

Dementia Associated with Alzheimer’s Disease Market Segmentation:

By Drug Class

Cholinergic/ Cholinesterase (ChE) Inhibitors
Donepezil
Galantamine
Rivastigmine
Memantine
Combined Drug (Memantine & Donepezil) and Others

By Distribution Channel

Hospital Pharmacies
Retail
Online Sales

By Region

Europe
North America
Asia Pacific
Latin America
Middle East & Africa

FutureWise Key Takeaways:

Growth prospects
SWOT analysis
Key trends
Key data-points affecting market growth

Objectives of the Study:

To provide with an exhaustive analysis on the dementia associated with Alzheimer’s disease market by drug class, by distribution channel, and by region
To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
To evaluate and forecast micro-markets and the overall market
To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa
To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
The customization Mobility Care offered are free of charge with purchase of any license of the report
You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com